Crizotinib

Crizotinib is a kinase inhibitor indicated for the treatment of patients with-

  • Metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive
  • Metastatic NSCLC whose tumors are ROS1-positive

There are no products to list in this category.